These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Therapy of neurological disorders in systemic vasculitis. Gold R; Fontana A; Zierz S Semin Neurol; 2003 Jun; 23(2):207-14. PubMed ID: 12894386 [TBL] [Abstract][Full Text] [Related]
26. Cutaneous necrotizing vasculitis and related disorders. Gilliam JN; Smiley JD Ann Allergy; 1976 Nov; 37(5):328-39. PubMed ID: 11718 [TBL] [Abstract][Full Text] [Related]
27. Quantitation of complement proteins in rheumatic disease. George D; Glass D Clin Rheum Dis; 1983 Apr; 9(1):177-98. PubMed ID: 6603322 [TBL] [Abstract][Full Text] [Related]
28. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option. Yoon KH Ann N Y Acad Sci; 2009 Sep; 1173():752-6. PubMed ID: 19758225 [TBL] [Abstract][Full Text] [Related]
29. [Vasculitis: current concepts]. Karsh J; Dorval G; Gilmore N; Osterland CK Union Med Can; 1976 Apr; 105(4):514-23. PubMed ID: 11599 [No Abstract] [Full Text] [Related]
30. [Circulating immunocomplexes in patients with various morbid conditions]. D'Amelio R; Milano CF; Le Moli S; Palmisano L Minerva Med; 1979 Dec; 70(57):3901-5. PubMed ID: 160999 [TBL] [Abstract][Full Text] [Related]
32. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases. Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381 [TBL] [Abstract][Full Text] [Related]
33. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Dejica D Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973 [TBL] [Abstract][Full Text] [Related]